ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrh

Arcutis today announced a new subgroup analysis in adults and adolescents with seborrheic dermatitis from STRATUM study...

Related Keywords

Hawaii , United States , Amanda Sheldon , Derek Cole , Investor Relations Advisory Solutions , Facebook , Nasdaq , Exchange Commission , Head Of Corporate Communications , Arcutis Biotherapeutics Inc , Clinical Dermatology Conference , Prescribing Information , Private Securities Litigation Reform Act , Nasdaq Arqt , Arcutis Biotherapeutics , Nc , Oryve , Seborrheic Dermatitis , Stratum , Winter Clinical , Topical Roflumilast , Foam ,